MedTrace Logo

Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine

NCT01738074 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10020

Last updated 2012-11-30

No results posted yet for this study

Summary

Assessment and evaluation the rotavirus gastroenteritis prevention effect and severe rotavirus diarrhea reducing effectiveness of human body, which inoculate trivalent rotavirus genetic reassortment vaccine.

Conditions

  • Randomized
  • Double-blind
  • Placebo Control Design

Interventions

BIOLOGICAL

trivalent rotavirus genetic reassortment vaccine

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • Center for Disease Control and Prevention, Henan Province

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Weeks
Max Age
13 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-06-30
Completion
2014-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01738074 on ClinicalTrials.gov